1. Orforglipron after Wegovy or Zepbound.
ATTAIN-MAINTAIN found that patients transitioned from tirzepatide or semaglutide to oral orforglipron (Foundayo) maintained substantially more of their prior weight reduction than patients switched to placebo. A new option in the maintenance discussion.
https://belite.com/orforglipron-maintenance-after-wegovy-zepbound/
2. CagriSema vs. Zepbound.
CagriSema delivered 23% average weight loss in its head-to-head trial — but did not prove non-inferior to tirzepatide (25.5%). It remains under FDA review, with a decision expected late 2026. What both numbers mean for patients.
https://belite.com/cagrisema-redefine-trials-weight-loss/
3. What the new GLP-1 pill changes.
Foundayo (orforglipron), approved in April, is the first GLP-1 pill with no food or water restrictions — and it joins the oral Wegovy pill as a second, very different oral option.
https://belite.com/foundayo-oral-glp-1-orforglipron-weight-management/
Related reading: our existing guides to protecting muscle during GLP-1 therapy and managing GLP-1 side effects and nutrition.
Muscle guide: https://belite.com/glp-1-muscle-loss-lean-mass-protein-strength-training/ — “How Much Muscle Do You Lose on GLP-1 Medications?” (published Aug 4)
Side effects: https://belite.com/side-effects-of-zepbound-what-you-need-to-know-before-starting-treatment/
Nutrition/protein: https://belite.com/how-to-maximize-weight-loss-success-for-patients-on-zepbound-or-wegovy/ — the protein-first eating guide
Clinical Pearl of the Week
Maintenance planning should begin before goal weight. The expanding range of oral and injectable options means long-term treatment can increasingly be individualized rather than treated as an all-or-nothing decision.
Myth vs. Fact
Myth: The less a patient eats on a GLP-1 medication, the better the treatment is working.
Fact: Excessive appetite suppression can compromise protein and micronutrient intake. Effective treatment should produce sustainable fat loss while preserving nutrition, strength, and function.
Questions we are watching
- Can oral maintenance preserve injectable-associated weight loss over several years?
- Will the FDA approve CagriSema late this year, and how will REDEFINE 4 shape its positioning?
- Which patients can safely use lower-dose or extended-interval maintenance?
- Which protein and resistance-training strategies best preserve muscle in older adults?
- How will higher-dose CagriSema and other multi-pathway therapies compare with established treatments?
About BeLite Medical Center
BeLite Medical Center in Northern, VA helps you reach your weight loss goals.
